miRagen Therapeutics (NASDAQ: MGEN) will announce its Q2 2020 financial results after market close on August 5, 2020. A conference call will follow at 4:30 p.m. ET, accessible via phone and webcast. miRagen specializes in RNA-targeted therapies, focusing on microRNAs to address significant medical needs. Its clinical candidates include cobomarsen, remlarsen, and MRG-110, aimed at treating various diseases such as blood cancers and heart failure. For more details, visit their investor website.
miRagen Therapeutics, Inc. (NASDAQ: MGEN) has regained compliance with Nasdaq's minimum bid price requirement as of July 1, 2020. The company was initially notified on October 28, 2019, that it failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. Compliance was achieved by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive trading days, with June 30, 2020 marking this achievement.
miRagen Therapeutics (NASDAQ: MGEN) announced promising preclinical data for MRG-229, a miR-29 mimic targeting Idiopathic Pulmonary Fibrosis (IPF). The candidate showed significant anti-fibrotic activity and safety in animal models, reversing pathological gene expression and reducing fibrosis. Preclinical studies indicated no toxicity at high doses. The company believes MRG-229 could be a differentiated treatment for IPF. A conference call on June 23, 2020, will further discuss the unmet needs in IPF and MRG-229's development.
miRagen Therapeutics (NASDAQ: MGEN) has appointed Lee Rauch as Chief Operating Officer, effective immediately. Rauch, a seasoned executive with over 25 years of biotech experience, will oversee business development, investor relations, and corporate communications. Her track record includes leadership roles at Global Blood Therapeutics and other companies. The executive team believes her expertise will enhance miRagen's position in advancing RNA-targeted therapies, including candidates targeting various cancers and cardiac diseases, potentially increasing shareholder value.
miRagen Therapeutics (NASDAQ: MGEN) is set to host a key opinion leaders (KOL) call on June 23, 2020, at 11 a.m. ET, focusing on idiopathic pulmonary fibrosis (IPF). The call will present new preclinical safety and efficacy data on MRG-229, a treatment targeting the low miR-29 levels in IPF. KOLs Dr. Fernando Martinez, Dr. Naftali Kaminski, and Teresa Barnes will share insights into the urgent medical needs in IPF management and address audience queries. MRG-229's development was supported by NIH/NHLBI funding, reflecting its potential significance in combating fibrotic diseases.
miRagen Therapeutics reported operational highlights and financial results for Q1 2020, showcasing a net loss of $8.0 million or $0.18 per share, an improvement from $11.6 million in Q1 2019. Cash and equivalents rose to $36.1 million. The company's COVID-19 impact is notable, particularly affecting the SOLAR trial, leading to delays in patient monitoring and dosing. Positive data for cobomarsen in Adult T-Cell Leukemia/Lymphoma was presented, with an FDA meeting planned in Q2 2020 for an expedited development path. Preclinical studies for MRG-229 are ongoing, bolstered by NIH funding.